| Ytd | 103.43% | |
| 1y | 198.10% |
| Open | 48.23 | Prev Close | 48.72 | Low | 47.61 | High | 48.86 | Mkt Cap | 3.38B |
| Vol | 1.64M | Avg Vol | 1.87M | EPS | -4.06 | P/E | N/A | Forward P/E | -16.25 |
| Beta | 0.94 | Short Ratio | 7.97 | Inst. Own | 97.63% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 44.53 | 200-d Avg | 27.95 | 1yr Est | 69.84 |
uniQure (QURE) reported earnings 30 days ago. What's next for the stock?
Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's
uniQure posts a wider Q2 2026 loss as revenues missed estimates, but regulatory progress for AMT-130
Wells Fargo analyst Yanan Zhu maintains uniQure (NASDAQ:QURE) with a Overweight and raises the pr
Wolfe Research analyst Rudy Li upgrades uniQure (NASDAQ:QURE) from Peer Perform to Outperform and
Wall Street analysts reshuffled their bets on Thursday as geopolitical fires, a Fed dissent surprise
Barclays analyst Eliana Merle maintains uniQure (NASDAQ:QURE) with a Overweight and lowers the pr
uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript
uniQure NASDAQ: QURE said it has aligned with the U.S. Food and Drug Administration on a potential a
uniQure (QURE) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate
uniQure (NASDAQ:QURE) reported quarterly losses of $(1.22) per share which missed the analyst consen
~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington's disease on track as planned for
~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~ ~ uniQure to host earn
QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business
QURE has soared on renewed AMT-130 optimism, but rich valuation, uneven earnings and pending regulat
QURE's AMT-130 is driving investor focus as FDA feedback, a targeted third-quarter 2026 filing and c
uniQure N.V. (QURE) reached a significant support level, and could be a good pick for investors from
Top Wall Street analysts upgraded and downgraded several top companies, including Applied Materials,
HC Wainwright & Co. analyst Patrick R. Trucchio maintains uniQure (NASDAQ:QURE) with a Buy an
Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its D
LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a lea
Mizuho analyst Uy Ear maintains uniQure (NASDAQ:QURE) with a Outperform and raises the price targ
LEXINGTON, Mass. and AMSTERDAM, June 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a lea
Dow Jones index fell 200+ points on Monday. Backblaze Inc rose 30.4% after $335M data storage deal w
LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a lea
uniQure reported early seizure reductions in an AMT-260 epilepsy study, with no treatment-related se
uniQure reports early AMT-260 epilepsy study data, with three patients showing 79-100% seizure reduc
FDA reverses its rejection of Regenxbio Navsunli, allowing the company to refile its gene therapy ap
QURE surges after the FDA said AMT-130 phase I/II data could support an accelerated approval filing
~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early b
Barclays analyst Eliana Merle upgrades uniQure (NASDAQ:QURE) from Equal-Weight to Overweight and
Goldman Sachs analyst Salveen Richter maintains uniQure (NASDAQ:QURE) with a Neutral and raises t
Leerink Partners analyst Joseph Schwartz maintains uniQure (NASDAQ:QURE) with a Outperform and ra
QURE is now a more credible Huntington's disease gene-therapy story after the FDA reopened a near-te
RBC Capital analyst Luca Issi maintains uniQure (NASDAQ:QURE) with a Outperform and raises the pr
U.S. stocks up, Dow Jones gains 0.39%. NASDAQ rose 0.09%, S&P 500 up 0.11%. Industrials shares j
uniQure stock surged after the FDA said three-year AMT-130 data could support accelerated approval f
U.S. stocks rose, with the Dow Jones gaining 200 points on Wed. Jabil Inc (JBL) shares surged 9.8% a
~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Ap
https://endpoints.news/acting-fda-commissioner-pledges-to-prevent-political-interference-in-rare-dis
US stocks up, Dow Jones up 171 pts. Replimune Group rises after FDA agreement. Other big gainers inc
https://subscriber.politicopro.com/article/2026/05/makarys-time-atop-fda-over-tktk-named-acting-comm
https://www.cbsnews.com/news/trump-approves-plan-to-fire-fda-commissioner-marty-makary/?intcid=CNM-0